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ABSTRACT
Alzheimer disease (AD) is a neurodegenerative disorder that leads to memory
impairment and cognitive dysfunction in elderly populations worldwide. A key
characteristic of AD is the formation of neuritic plaques composed of extracellularly
deposited aggregates of amyloid-β (Aβ), an intrinsically disordered protein. Although Aβ
fibrils were once thought to be the prime initiators of the disease, research has since been
shifted to consider soluble, low molecular weight Aβ oligomers as the driving force behind
AD toxicity. Due to its origin as a cleavage product of amyloid precursor protein (APP),
an integral membrane protein, Aβ is known to perpetually interact with a variety of
membrane lipids. We have previously characterized oligomerization of Aβ42 with lipid
and fatty acids as well as GM1 ganglioside, an abundant component of membrane lipid
rafts. These oligomers, coined GM1Os, exhibit unique biochemical and biophysical
properties. Additionally, low levels of neurotransmitters such as acetylcholine (ACh) and
dihydroxyphenylacetaldehyde (DOPAL) have been implicated in the onset of AD. This
project involves the characterization of GM3- and GD3- bound Aβ42, which exhibits
distinct properties, conformation, and effects on Aβ aggregation. Similarly, ACh and
DOPAL were found to inhibit the aggregation of Aβ, confirming correlation between low
levels of neurotransmitters and plaque formation. These findings suggest that different
neuronal gangliosides interact differently with Aβ, which has implications on the varying
degrees of toxicity in clinical AD pathology.
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INTRODUCTION
1.1 Alzheimer disease
Alzheimer disease (AD) is a neurodegenerative disease that affects approximately
44 million people internationally, a figure that is projected to nearly double by 20301.
Characterized by progressive loss of cognitive function and memory among elderly
patients, AD has increasingly become an issue for medical systems to navigate as the
average life expectancy increases2. There are two major types of lesions involved in
neuronal dysfunction and toxicity: intracellular neurofibrillary tangles and extracellular
neuritic plaques. The neurofibrillary tangles, composed of hyper-phosphorylated tau
proteins, lead to neuronal death 3. The neuritic plaques are deposits of Amyloid-β (Aβ)
peptide aggregates that abundantly assemble in the limbic systems of AD-afflicted brains,
causing damage to neurons in plaque vicinity2.

1.2 Aβ
Following the isolation of Aβ peptide from both cerebral amyloid angiopathy
(CAA) amyloid deposits and AD neuritic plaques from post mortem brains in the 1980s,
the mechanisms behind the generation of Aβ and its plaques have been vastly studied4–6.
Aβ is produced upon proteolytic cleavage of amyloid precursor protein (APP), a type I
integral membrane protein located within the central nervous system with a localized
isoform consisting of 695 amino acids7. Under conditions that remain unclear, APP can
be cleaved by α-secretase to generate soluble protein fragments; this process is called the
non-amyloidogenic pathway. Aβ, however, is produced in the amyloidogenic pathway, in
which APP is sequentially cleaved into fragments by β-secretase and γ-secretase8. The
2

Aβ monomers produced by this cleavage are intrinsically disordered and its isoforms can
have 39 to 43 amino acid residues, with Aβ40 and Aβ42 isoforms being the main
components in neuritic plaques6,8,9.
In the early 1990s, Hardy and Higgins proposed the amyloid cascade hypothesis,
suggesting that deposits of Aβ fibrils were the main contributors to the onset of AD
symptoms, triggering neurofibrillary tangle formation and neuronal death in response9.
Revisions to the amyloid cascade hypothesis were prompted upon the discovery of Aβderived diffusible ligands (ADDLs), soluble Aβ oligomers that were neurotoxic in
organotypic mouse brain slice cultures in the absence of insoluble fibrils10. This
discovery, corroborated with significant indication that amyloid plaque formation could
not be directly linked to synapse loss or cognitive decline in AD-afflicted brains, has
shifted research focus on the propagation of these soluble Aβ oligomers, which are
hypothesized to initiate toxic pathways much earlier than the formation of plaques11,12.
Much evidence has since been reported that interactions of Aβ with proteins involved in
other neurodegenerative diseases, metal-ions, and various other metabolites uniquely
influence aggregation kinetics, oligomerization, and AD pathology compared to
homotypic Aβ fibrillar formation13–15.

1.3 Possible effects of neurotransmitters on Aβ aggregation
Following the proteolytic cleavage of APP, Aβ is formed in the extracellular
space and is consequentially prone to interact with a variety of neurotransmitters, which
are abundant in the synaptic cleft. Since studies first indicated drastically decreased levels
of choline acetyltransferase (CAT) in AD brain biopsies, it has been documented that low
3

levels of neurotransmitter acetylcholine (ACh) are likewise corroborated with the
disease16–18. In the basal forebrains of AD-afflicted brains, neurons responsible for the
release of ACh degenerate selectively during the onset of the disease. We have also
established that the protein α-synuclein (αS), the primary causative agent of Parkinson’s
disease, interacts with dopamine metabolite dihydroxyphenylacetaldehyde (DOPAL) to
form unique oligomers called DOPAL-derived αS oligomers (DOPAL-SOs). The crossseeding of Aβ42 with these DOPAL-SOs formed conformationally distinct fibrils19.
Despite the significant evidence that AD pathology is linked to neurotransmitters like
ACh and DOPAL, the mechanism and effect of their interaction with Aβ is still poorly
understood. A key step in understanding the role of neurotransmitters in neuritic plaque
formation is to characterize neurotransmitter-Aβ oligomers with distinct conformations
and biophysical properties.

1.4 Aβ-lipid interactions
Inherent to its origin from the transmembrane protein APP and its amphipathic
nature, Aβ has a strong affinity toward membrane phospholipids to generate aggregates
with varying levels of cytotoxicity20–23. However, the formation of lipid-induced fibrils is
contingent upon various conditions in vitro. For instance, anionic phospholipids have
been shown to increase Aβ fibrillar formation, but only when certain structural moieties,
including fatty acids, phosphate groups, and C-terminal aliphatic amino acids, are
present24. It has also been shown that lipids differentially influence the mechanism of
fibrillar formation, including the rate of aggregation of monomeric Aβ versus oligomeric
Aβ, as well as mutant Aβ25–28.
4

Furthering the endeavor to understand Aβ-lipid interactions, our lab has
characterized multiple distinct oligomer conformations in the presence of lipids. For
example, it was determined that conformationally distinct low-molecular weight Aβ
oligomers result from propagation with non-esterified fatty acids (NEFAs), which are
copious within the brain29. Shortly after, these oligomers, coined large fatty acid-derived
oligomers (LFAOs), were found to initiate the conversion of Aβ42 monomers into
LFAOs30. This work was corroborated with the characterization of LFAO-seeded fibrils,
which presented distinct conformations opposed to homotypic Aβ fibrils31.
Ganglioside interactions with Aβ have also been a focal point in understanding
the influence of lipids on Aβ aggregation. Following the characterization of a novel GM1
ganglioside-bound Aβ species by Yanagisawa et al., it was been established that GM1, a
chief constituent of lipid rafts found abundantly in neurons, instigates a β-sheet transition
state in Aβ monomer32,33. Similar to LFAOs, GM1-bound Aβ has also been shown to seed
the fibrillation of monomeric Aβ in membranes mimicking the lipid composition of
rafts34. Recent data from our lab established that GM1-dervied oligomers (GM1Os)
exhibit unique conformations, biophysical characteristics, and cytotoxicity to a greater
extent than anionic lysophosphatidyl glycerols (LPGs), which were biophysically similar
to LFAOs35.
Interestingly, it has been suggested that the location of Aβ plaque distribution in
the brain is moderated by different gangliosides. Yamamoto et al. reported that the
aggregation of hereditary Aβ variants in different regions of the brain is influenced by the
type of ganglioside abundant in such region. For instance, GM3 ganglioside positively
influenced the aggregation of Dutch- and Italian-type Aβ variants, while GD3 ganglioside
5

enhanced aggregation of the Flemish-type Aβ variant. This suggests that the localization
of Aβ to a particular region of the brain is ganglioside-dependent36.

1.5 Focus of this research
Motivated by the lack of understanding surrounding the pathology of Aβ
oligomers in AD, we aim to characterize Aβ oligomers generated from both
neurotransmitter interactions and with ganglioside-enriched lipids to investigate their
biophysical properties. Such an investigation would lead to discoveries on oligomer strain
generation with distinct conformations implicated in various phenotypes observed in
patient brains.
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MATERIALS AND METHODS
2.1 Materials
The C8 Zorbax semi-prep HPLC column was purchased from Agilent. The size
exclusion chromatography (SEC) column (Superdex-75 HR 10/30) used to purify
monomers was bought from GE Life Sciences (Marlborough, MA). Ab5 monoclonal
antibody was obtained from the laboratory of Dr. Levites (University of Florida,
Gainesville). Acetylcholine (ACh) was purchased from Sigma-Aldrich, while DOPAL
was purchased from Cayman Chemicals (Ann Arbor, Michigan). Lipid stocks (GM1 and
GM3) were procured from Avanti Polar Lipids, Inc (Alabaster, AL).

2.2 Preparation of Aβ monomers
Wild type Aβ42 plasmid obtained from Addgene was used to transform
Escherichia coli BL21 (DE3) cells, which were then grown in LB broth containing
ampicillin to an optical density (OD) of 0.7 at 600 nm and induced with 1 mM IPTG for
16-18h at 37º C. Cells were harvested at 9500 xg for 15 minutes and cell pellets were
stored at -20° C. For Aβ purification, cells were resuspended in TE buffer (20 mM Tris,
pH 8.0, 1 mM EDTA and subjected to 10 sonication cycles (30 second burst, 1 minute
rest). Sonicated cells were centrifuged at 9500 xg for 15 minutes and the pellet was again
resuspended in TE buffer and sonicated for 8 cycles (30 second burst, 1 minute rest),
before being centrifuged at 9500 xg for 15 minutes. The pellet was again resuspended in
buffer for 6 sonication cycles (30 second burst, 1 minute rest). The resulting pellet
containing the inclusion bodies was then resuspended in TE buffer containing 4 M Urea
and sonicated for 6 cycles. The supernatant collected from centrifugation was filtered
7

through a hydrophilic PVDF membrane (Millipore Sigma) into 1 mL aliquots into
siliconized Eppendorf tubes and stored at -80º C until needed for HPLC purification.
1 mL aliquots of Aβ were loaded onto a C8 Zorbax semi-prep HPLC column that
had been preheated for 45 minutes in an 80º C water bath. The column was attached to an
HPLC system that had been preheated to 66.5ºC, and reversed phase HPLC was
completed with a starting gradient of 95% (v/v) H2O and 5% (v/v) acetonitrile and a flow
rate of 1.5 mL/min. Samples were collected in 1 mL fractions. A Cary 50-UV-vis
spectrometer (Agilent Technologies, Inc; Santa Clara, CA) was used to determine
concentration of Aβ in collected fractions, and samples were lyophilized before storing at
-80º C for subsequent SEC chromatography purification of Aβ monomers.
Before loading onto the SEC column (Superdex-75 HR 10/30), lyophilized Aβ
peptide stored at -80º C was dissolved in nanopure H2O (490µL) for 30 minutes at room
temperature and NaOH (10 mM) for 10 minutes. The Superdex-75 HR 10/30 SEC
column was then connected to a BioLogic DuoFlowTM chromatography system, and Aβ
in NaOH was ran in 20 mM Tris buffer (pH 8.0) at a rate of 0.5 mL/min at 25º C. The
purified monomers were collected and the appropriate monomer fractions were pooled.
The Aβ concentration was determined with a Cary 50-UV-vis spectrophotometer, using a
molar extinction coefficient of 1450 M-1 cm-1 at 276 nm. To validate the purity of the Aβ
monomers, matrix-assisted laser desorption time-of-flight mass spectrometry (MALDITof) was performed. Purified monomers were stored in siliconized Eppendorf tubes at 4º
C and used within 5-6 hours.
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2.3 Thioflavin-T fluorescence
Aggregation kinetics of Aβ and its reaction with other biomolecules were
monitored by thioflavin-T (ThT) fluorescence for 48 hours at 37º C in a BioTek Synergy
96 well plate reader. Neurotransmitter reactions were carried out with Aβ monomer (25
µM) with various concentration of acetylcholine (0.1, 10, and 50 mM) and DOPAL (0.1,
0.5, 1.75, 2.5, 3.5 mM) in the presence of 50 µM ThT in 20mM Tris buffer (pH-8.0).
Ganglioside reactions were carried out similarly, with Aβ monomers (25 µM) in 20 mM
Tris (pH 8.0), 50 mM NaCl, and 50 µM ThT, with 75 µM GM1, 400 µM GM3, 100 µM
GD3, and 400 µM GD3 micelles, respectively. Each reaction was transferred in 200 µL
aliquots to a Corning 96-well plate (black plates) for aggregation kinetics. Samples were
excited at 452 nm, and ThT fluorescence was obtained with an emission at 485 nm at
every 10 minutes at 37ºC with shaking.

2.4 Gel electrophoresis and immunoblotting
Prior to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE),
1X Laemmli loading buffer containing 1% (w/v) SDS was added to samples before
loading onto a 4%-20% (w/v) Bis-Tris Bio-Rad TGX gel without heating. For fragment
molecular weight comparison, pre-stained molecular weight markers (Novex Sharp
Protein Standard, Life Technologies) were ran in parallel. Following PAGE denaturation,
gels were immunoblotted onto a 0.2 µM nitrocellulose membrane (Bio-Rad) and boiled
in 1X PBS (pH 7.4) in a microwave oven for 1 minute. The immunoblot was then
blocked in 1X PBS (pH 7.4) containing 5% (w/v) nonfat dry milk and 1% (v/v) Tween20 for 1.5 hours at 25º C, before being probed overnight with Aβ-specific Ab5
9

monoclonal antibody (1:6000 dilution) at 4º C. An anti-mouse, horseradish peroxidaseconjugated secondary antibody (1:6000 dilution) was then used to probe the immunoblot
for 1.5 hours at 25º C. Blots were then imaged using a GelDoc molecular imager (BioRad) and a Super SignalTM West Pico Chemiluminescent Substrate kit (Thermo Fisher
Scientific).

2.5 Digestion with Proteinase K (PK)
PK digestion was carried out by mixing 5 µM samples of Aβ-GM1 and Aβ-GM3
samples and 2 nM PK diluted from 20 mg/mL stock solution (Ambion Corporation) to a
10 nM stock in 20 mM Tris (pH 8.0) and incubating the reactions at 37º C while shaking
at 200 rpm. Reactions were then quenched with 0.5 mM PMSF at time intervals of 10,
20, 30, and 40 minutes. SDS PAGE was then carried using 1% (w/v) SDS-PAGE and
immunoblotted with Ab5 monoclonal antibody for imaging.
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RESULTS
3.1 Neurotransmitters ACh and DOPAL inhibit Aβ42 aggregation
The effect of neurotransmitters ACh and DOPAL on Aβ42 aggregation kinetics
were monitored by ThT binding at 37º C for 24 hours. In these assays, we saw that
increasing concentrations of ACh induced an increase in the lag times of Aβ42
aggregation (Fig. 1A). The lowest stoichiometry of ACh (100 µM) showed a lag time of

Figure 1: ThT fluorescence of Aβ interactions with neurotransmitters. (A) Aggregation kinetics of 10 µM
Aβ in 20 mM Tris Buffer (pH 8.0) and 50 µM ThT with 10 mM ACh (1, black squares), 50 mM ACh (2, red
circles), 100 µM ACh (3, blue triangles), and Aβ control alone (4, magenta triangles). (B) Aggregation kinetics
of 10 µM Aβ in 20 mM Tris Buffer (pH 8.0) and 50 µM ThT with 100 µM DOPAL (1, black squares), 500 µM
DOPAL (2, red circles), 1.75 mM DOPAL (3, blue triangles), 2.50 mM DOPAL (4, magenta triangles), 3.50 mM
DOPAL (5, green diamonds), and Aβ control (6, navy triangles). (C) Western blot following SDS-PAGE of the
incubation of 10 µM Aβ in 20 mM Tris Buffer (pH 8.0) with 10 mM ACh (1), 50 mM ACh (2), 100 µM ACh (3),
and Aβ control (C). (D) Western blot following SDS-PAGE of the incubation of 10 µM Aβ in 20 mM Tris Buffer
(pH 8.0) with 100 µM DOPAL (1), 500 µM DOPAL (2), 1.75 mM DOPAL (3), 2.50 mM DOPAL (4), 3.50 mM
DOPAL (5), and Aβ control (C) at 4 and 16 hours, respectively.
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7-8 hours, close to the control of Aβ42 alone, indicating that in our experimental setup,
100 µM of Ach had no effect on the aggregation rate of Aβ42. At the higher
concentrations of ACh, however, lag times of Aβ42 aggregation increased, with 10 mM
ACh inducing aggregates at 11-12 hours and 50 mM ACh inducing aggregates at 24
hours (Fig. 1A). This suggests that higher concentrations of ACh inhibit Aβ42
aggregation. Following incubation of the same reactions at 37º C for 24 hours, SDSPAGE confirmed that 50 mM ACh inhibited Aβ42 aggregation, as indicated by the
diminished intensity of molecular weight band in the fibril region as opposed to the
control (Fig. 1B). Figure 1C shows ThT fluorescence analysis of the DOPAL induced
Aβ42 aggregates. At each concentration of DOPAL, the lag time of Aβ42 was
significantly increased, suggesting that each tested concentration of DOPAL inhibited
Aβ42 aggregation. A parallel analysis of these samples by SDS-PAGE and Western Blot
showed the control Aβ42 in the absence of neurotransmitters formed a high molecular
weight band that failed to enter the gel, indicating fibril formation (Fig. 1D, Lane C). In
contrast, samples incubated with DOPAL showed no such bands but a prominent
monomeric band near 4.5 kDa, suggesting that DOPAL effectively inhibited aggregation
correlating to the ThT data (Fig. 1D, Lanes 2-5, 4 hours; Lanes 1-5, 16 hours).

3.2 The effect of GM3 and GD3 ganglioside micelles on Aβ42 aggregation.
Previous data in our laboratory indicated that lipid surface characteristics can alter
the course Aβ aggregation to generate unique oligomers35. To see whether differences in
carbohydrate distributions on gangliosides have a similar effect on Aβ aggregation, GM3,
GD3 and GM1 ganglioside micelles were incubated with Aβ42 and aggregation was
12

monitored (Fig. 2A). Our analysis showed that each concentration of ganglioside micelles
induced aggregation of Aβ42 before the lag time of the control, suggesting that all
gangliosides tested increased the rate of Aβ42 aggregation (Fig. 2A).

Figure 2: Interactions of gangliosides GM3 and GD3 with Aβ. (A) ThT fluorescence of 25 µM Aβ with
75 µM GM1 (1, black squares), 400 µM GM3 (2, red circles), 400 µM GD3 (3, blue triangles), 100 µM GD3
(4, magenta triangles), and Aβ control (5, green diamonds) in 20 mM Tris (pH 8.0), 50 mM NaCl, and 50 µM
ThT (B) Incubation of 25 µM Aβ with 75 µM GM1 (1), 400 µM GM3 (2), and Aβ control (3) in 20 mM Tris
(pH 8.0) and 50 mM NaCl at time frames of 6 hours, 10 hours, and 24 hours. (C) Incubation of 25 µM Aβ
with 400 µM GD3 (1), 100 µM GD3 (2), 400 µM GM3 (3), and 75 µM GM1 (4) in 20 mM Tris (pH 8.0) and
50 mM NaCl. (D) Proteinase K digestion of 25 µM Aβ and 400 µM GM3 for time intervals of 10, 20, 30, and
40 minutes with Aβ control to the right. (E) Proteinase K digestion of 25 µM Aβ with 75 µM GM1 and 100
µM GD3 for time intervals of 10, 20, 30, and 40 minutes. Aβ control labeled C.

After incubation of with GM3, Aβ formed high molecular weight (HMW)
aggregates after 10-24 hours (Fig. 2B), along with fibrils. Upon centrifugation and
isolation by SEC, the presence of the HMW aggregate band diminished, indicating that
Aβ did not form a stable oligomer (Fig. 3A). Incubation of Aβ with GD3 likewise formed
HMW aggregates after 24 hours (Fig. 2C), along with fibrils. However, soluble oligomers
13

were able to be separated using centrifugation and isolation by SEC. The isolated
aggregates of Aβ-GD3 did appear to be stable and oligomeric (Fig. 3B).
Proteinase K (PK) digestion is commonly used to assess enzymatic stabilities of
aggregates, which also reflects the conformational differences and similarities among
aggregates37–39.
Therefore, PK was
used to determine
conformational
differences and
stability of the
oligomers formed in
the presence of GM3and GD3-induced
Aβ42 aggregates.
Figure 2D displays
the Western Blot of
Figure 3: SDS-PAGE of Aβ aggregates isolated by SEC. (A) GM3induced Aβ aggregates and (B) GD3-induced Aβ aggregates. SEC fractions
are labeled accordingly.

PK digestion with 400
µM GM3-induced Aβ

aggregates at time intervals of 10, 20, 30, and 40 minutes. The HMW oligomer band
begins to diminish after 10 minutes of digestion; however, GD3-Aβ42 aggregates seem to
withstand PK digestion throughout each digestion time (Fig. 2E). As seen by the
diminishing oligomeric band at 30 and 40 minutes, GD3-Aβ42 aggregates withstood
digestion to a lesser extent than the established GM1-induced Aβ oligomer (Fig. 2E).
14

These results suggest that Aβ-GM3 and Aβ-GD3 are digested differently than the
established Aβ-GM1 oligomer, and in turn establish that these oligomers have possible
conformational differences.
3.3 Expression and purification of recombinant AβE22D (Osaka) mutant
Aβ with a deletion mutation at amino acid position 22 are refered to as the Osaka
variant (AβE22D), which has been shown to increase the rate of oligomer formation,
causing symptoms of AD to appear earlier than the typical patient age range40. We sought
to determine the effects of this mutant in the presence of the ganglioside lipids not only to
uncover the significance of the glutamate residue in oligomer formation but also to
provide support for the potential role of gangliosides in pathogenesis with Osaka variant.
We therefore designed experiments to determine the effects of GM1, GM3 and
GD3 on Aβ Osaka oligomerization. Osaka Aβ42 was subcloned into a plasmid at the
Florida State University Cloning Facility and subsequently used to transform competent
Escherichia coli BL21 (DE3) cells. Cultures were checked for expression via dot blot

Figure 4: Recombinant Aβ Osaka variant transformation and purification. (A) Aβ Οsaka
expression check dot blot. (B) HPLC purification of recombinant Aβ Osaka. (C) Mass spectrometry
analysis of HPLC-purified Aβ Osaka.
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(Figure 4A), and colony 10 was selected for purification. Purification of recombinant Aβ
Οsaka colony 10 was conducted in the standardized recombinant wildtype Aβ42
purification and extraction method outlined in the Methods section. HPLC analysis
showed that the peak typical of WT Αβ42 at 18 minutes was present (Figure 4B),
indicating that recombinant Aβ Οsaka purification was successful. MADLI-TOF mass
spectrometry confirmed that the obtained protein was purified recombinant Aβ Osaka
(theoretical mass: 4513 Da).
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DISCUSSION
The results presented here are aimed at increasing our understanding of Aβ
oligomerization and thus their role in AD pathogenesis. Studies over the last decade have
revealed the relevance of the oligomeric forms of Aβ to toxicity in AD, warranting
studies focusing on factors that affect their formation13-15. Also, structural differences in
the oligomeric forms of the protein have been shown to give rise to different pathological
phenotypes in AD19,35. Accordingly, we investigated the oligomerization of Aβ in the
presence of
gangliosides and
neurotransmitters
and characterized
their
conformational
differences. Here,
we have shown data
that suggests that
differences in
ganglioside
structures
contribute to these
differential
Figure 5: Structure of gangliosides GM1 (A), GM3 (B), and GD3 (C).

pathways in Aβ
aggregation.
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All gangliosides share a common ceramide attached to the lipid tail and a sialic acid
connected to its carhbohydrate chain, but have distinction in their carbohydrate moieties
(Fig. 5). Our results suggest that these chemical differences may manifest to differences
in their interactions with Aβ (Fig. 2, Fig. 3). With all gangliosides tested here (including
GM1, GM3, and GD3), the rate of Aβ42 aggregation was increased over controls (Fig.
2A). As compared to the stable, isolated GM1O established in the Rangachari lab 35,
GM3- and GD3- induced oligomers also exhibit conformational differences with regard
to their stability in the presence of PK (Fig. 2D, Fig. 2E). GD3-bound Aβ42 forms a more
stable oligomer upon isolation and withstands PK digestion to a greater extent than GM3bound Aβ42. Despite this finding, neither the GD3-bound Aβ42 or GM3-bound Aβ42
formed oligomers as stable as the established GM1O35. Differences in ganglioside
composition is seen in various anatomical regions of the brain36,41. Our results are well
aligned with the hypothesis that membrane constituents and surface characteristics
contribute to the formation of different aggregation pathways and conformationally
distinct oligomers32–35.
The precise effect of neurotransmitters on the aggregation of Aβ has not been fully
established. We believed that, alongside gangliosides, neurotransmitters modulate the
aggregation and oligomerization of Aβ. My results on the effect of neurotransmitters on
Aβ42 aggregation suggest that high concentrations of ACh and all tested concentrations
of DOPAL inhibit the rate of aggregation. These findings, paired with the known loss of
cholingeric neurons in AD pathology, suggest that possible remedies to the disease might
involve endeavors to reintroduce these neurotransmitters to the synaptic cleft16-18.

18

Overall, these results represent a preliminary step in understanding how the complex
biochemistry of the neuronal environment affects the aggregation of Aβ. Here, we have
established the potential role of neuronal gangliosides and neurotransmitters as
modulators of Aβ aggregation, suggesting their use as therapeutic targets.
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